Bagsværd, Denmark, 20 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonSylvie Louise Grégoire 2 Reason for the notification a)Position/statusMember of the Board of Directors b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument,
type of instrument,ADRs
Identification codeNVO b)Nature of the transactionPurchase of ADRs c)Price(s) and volume(s) Price(s)Volume(s) DKK 913.152 ADRs DKK 913.05200 ADRs DKK 912.751 ADRs DKK 912.68431 ADRs DKK 912.61232 ADRs DKK 912.55379 ADRs DKK 912.34255 ADRs d)Aggregated information Aggregated volumePrice
1,500 ADRs
DKK 1,368,944.39 e)Date of the transaction2024-08-19 f)Place of the transactionNew York Stock Exchange
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: Ambre James-Brown
+45 3079 9289
[email protected]
Liz Skrbkova (US)
+1 609 917 0632
[email protected]Investors: Jacob Martin Wiborg
